GlassScriptPhysician profile
Duane M Gels
NPI 1609875319
$3,813.41
in general payments reported to CMS, 2019-2025
23 companies · $1,012 in 2025
The $1,012 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $144 · 2021: $350 · 2022: $424 · 2023: $404 · 2024: $812 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,203 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,203.16 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $645.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $559.24 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $487.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $408.63 | 2019-2025 | Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $353.96 | 2019-2023 | Dupixent |
| Kaleo, INC. | $200.44 | 2019-2024 | Auvi-Q |
| Pfizer INC. | $198.33 | 2019-2025 | |
| Genentech USA, INC. | $190.77 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $169.15 | 2025 | Neffy |
| Blueprint Medicines Corporation | $133.36 | 2023-2025 | Ayvakit |
| Amgen INC. | $107.77 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $58.30 | 2021-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $48.04 | 2025 | Dawnzera |
| Aimmune Therapeutics, INC. | $41.17 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.86 | 2025 | Takhzyro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $36.65 | 2019-2023 | Pre-Pen, Alternaria Tenuis, Grastek |
| Pharming Healthcare, INC. | $28.84 | 2024 | Ruconest |
| Aytu Biopharma, INC. | $28.50 | 2024 | Karbinal |
| Paratek Pharmaceuticals, INC. | $21.23 | 2025 | Xhance |
| Merck Sharp & Dohme LLC | $18.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.23 | 2021 | |
| Philips North America LLC | $14.39 | 2022 | |
| Optinose US, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duane Gels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.